iRadimed Corporation (IRMD) to Issue Quarterly Dividend of $0.20 on May 29th

iRadimed Corporation (NASDAQ:IRMD) declared a quarterly dividend on Friday, May 1st. Shareholders of record on Friday, May 15th will be given a dividend of 0.20 per share by the medical equipment provider on Friday, May 29th. This represents a c) dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Friday, May 15th.

iRadimed has a dividend payout ratio of 40.2% meaning its dividend is sufficiently covered by earnings. Research analysts expect iRadimed to earn $2.16 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 37.0%.

iRadimed Stock Performance

IRMD stock opened at $87.15 on Friday. iRadimed has a fifty-two week low of $50.31 and a fifty-two week high of $107.90. The business’s 50-day moving average is $96.69 and its two-hundred day moving average is $94.02. The company has a market cap of $1.11 billion, a price-to-earnings ratio of 47.62 and a beta of 0.91.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The company had revenue of $21.98 million for the quarter, compared to the consensus estimate of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Equities analysts predict that iRadimed will post 1.94 earnings per share for the current year.

Insider Transactions at iRadimed

In related news, CEO Roger E. Susi sold 3,750 shares of iRadimed stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $89.16, for a total transaction of $334,350.00. Following the sale, the chief executive officer owned 2,198,750 shares of the company’s stock, valued at approximately $196,040,550. This trade represents a 0.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 48,750 shares of company stock worth $4,708,950. 36.80% of the stock is currently owned by company insiders.

Institutional Trading of iRadimed

Several institutional investors and hedge funds have recently added to or reduced their stakes in IRMD. Fifth Third Bancorp purchased a new position in iRadimed during the 1st quarter valued at approximately $198,000. Y Intercept Hong Kong Ltd purchased a new position in iRadimed during the 1st quarter valued at approximately $334,000. Inspire Investing LLC purchased a new position in iRadimed during the 1st quarter valued at approximately $107,000. SG Americas Securities LLC grew its holdings in iRadimed by 4.5% during the 1st quarter. SG Americas Securities LLC now owns 73,561 shares of the medical equipment provider’s stock valued at $7,081,000 after buying an additional 3,170 shares in the last quarter. Finally, Hsbc Holdings PLC grew its holdings in iRadimed by 19.2% during the 4th quarter. Hsbc Holdings PLC now owns 21,559 shares of the medical equipment provider’s stock valued at $2,103,000 after buying an additional 3,468 shares in the last quarter. Institutional investors own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.